FDA Press Announcements · Today
FDA grants breakthrough therapy designation for novel GLP-1 agonist
Designation accelerates the review timeline for late-stage metabolic disease candidates. Precedent-setting for the therapeutic class.
05:58 — before anyone opens their laptop
The intelligence brief your R&D team actually reads.
Sightline delivers a personalised biotech and pharma intelligence brief to your team every morning, tuned to your pipeline, your competitors, and the regulators that matter to you. Set up in 5 minutes.
Want to see it first?
Built on the same pipeline that powers a UK energy company’s news monitoring.
SightlineToday · 06:00
- Regulatory
FDA grants breakthrough therapy designation for novel GLP-1 agonist
FDA Press Announcements · why it matters: accelerated pathway precedent
- Competitor
AstraZeneca Phase III trial for KRAS inhibitor meets primary endpoint
Endpoints News · why it matters: competitive pipeline pressure
- Regulator
MHRA publishes updated guidance on AI-assisted drug discovery submissions
MHRA Alerts · why it matters: submission strategy review
Delivered while the office was still dark
Most biotech teams piece together competitive intelligence from a dozen disconnected sources.
Someone scans PubMed, BioPharma Dive, and clinical trial registries for hours each week, and still misses competitor pipeline moves that matter.
FDA and MHRA updates get buried in email threads, and no one connects the regulatory dots until the quarterly review.
The competitive landscape analysis becomes a week-long research sprint, because no one's been tracking through the quarter.
The information you need exists.
The signal-to-noise is broken.
How Sightline works
From signup to sharper-than-yesterday in four steps.
Five minutes of setup tonight. Your first brief at 06:00 tomorrow.
Tonight · 21:32 — Step 1 of 4 · Setup
Tell us about your business in 5 minutes.
Sightline asks 12 questions about your therapeutic focus, pipeline, competitors, and the regulators you track. It captures everything our pipeline needs to deliver content that reads like a junior analyst who’s been on your team for a year.
IndustryStakeholdersCompetitorsRegionReporting cadenceTopics to mute
Business planPipeline overviewCompetitor list
Waiting for a company name…
No abstract questions. No 200-field forms. Real questions about your business, answered in 5 minutes.
Tonight · 21:37 — Step 2 of 4 · Calibration
Show the system what relevant looks like.
You react to 30 real candidate articles — 👍 love, 👎 hate, 🎯 especially yes, 🤷 nuanced. The system uses your reactions to calibrate the classifier rubric before sending you anything. Most onboarding asks you to fill in keywords and hope. Sightline shows the system your actual taste.
Try it — react to a couple below
Endpoints News · 2h ago
AstraZeneca Phase III trial for KRAS inhibitor meets primary endpoint
Topline data shows statistically significant progression-free survival benefit. Direct overlap with your oncology pipeline.
BioWorld · Yesterday
Seed-stage biotech raises £3m for AI-driven target discovery
Generic funding announcement — no clinical or regulatory signal for your business.
MHRA Alerts · 3d ago
MHRA publishes updated guidance on AI-assisted drug discovery submissions
New submission requirements for AI-derived candidate data take effect this autumn. Review your regulatory strategy now.
Calibrating rubric — 0 of 4 sample reactions
Your rubric is being calibrated — you prefer clinical results and regulatory decisions over funding news.
Tomorrow · 05:59 — Step 3 of 4 · Your first brief
Your team’s morning brief, ready before anyone opens their laptop.
Each morning Sightline delivers a brief tuned to your business: 5–10 articles that matter, each with a “why this matters to you” annotation written for your specific context. Delivered straight to email — or posted to your team’s Slack channel.
While you sleptScanned 0 articles · kept 0
Sightline· Tue 06:00 · to your team5 stories · 4 min
Pipeline · STAT News
Roche's oral PI3K inhibitor meets primary endpoint in Phase III HR+ breast cancer trial
Topline data shows a 4.8-month improvement in progression-free survival versus standard of care.
Why this matters: Same target class as your preclinical candidate — worth citing in your next investor update.
Regulatory · FDA Press Announcements
FDA grants breakthrough therapy designation for novel GLP-1 agonist
Designation accelerates the review timeline for late-stage metabolic disease candidates.
Why this matters: Sets a precedent for accelerated review in your therapeutic class — flag to your regulatory affairs lead.
Competitor · Endpoints News
AstraZeneca Phase III trial for KRAS inhibitor meets primary endpoint
Topline data shows a statistically significant progression-free survival benefit.
Why this matters: Direct overlap with your oncology pipeline — worth a competitive teardown before your next board update.
Research · MHRA Alerts
MHRA publishes updated guidance on AI-assisted drug discovery submissions
New submission requirements for AI-derived candidate data take effect this autumn.
Why this matters: Your data science team's target-discovery pipeline falls within scope — review your regulatory strategy now.
Every morning after — Step 4 of 4 · Learning
Sharpens itself as your team uses it.
Every article has a 👍/👎 button. Your team’s reactions feed back into the classifier rubric over time. By month 3, most teams report Sightline catches things their previous monitoring missed and skips things their previous monitoring surfaced.
From this morning’s brief
1 of 4
STAT News
Roche's oral PI3K inhibitor meets primary endpoint in Phase III trial
Team reactions
Every brief, every article
Classifier rubric
Recalibrated continuously · 0 updates
Tomorrow’s brief
Sharper than yesterday’s
What you get
One subscription. Ten deliverables. All from one pipeline.
InboxYour quarter with Sightline
- DailyTue 06:00
Your morning brief — 5 stories · 4 min
Email or Slack, before anyone opens their laptop
- DailyTue 09:12
Mention alert: Ofgem cites your sector in charging consultation
Real-time alerts on your company, competitors, and regulators
- WeeklyMon 07:00
Executive summary — “3 things to know”
+ categorised digest of the week
- Monthly1st · 07:30
Trend report — ready for internal committees
Auto-generated, no analyst hours spent
- QuarterlyEvery 90 days
Quarterly briefing — 90-day deep view
Ready for board / leadership reporting
On-demand · anytime
- 5-min onboarding wizard (re-runnable anytime)
- Curator commentary overlay — add your team's notes before briefs go out
- Custom source curation tuned to your business
- Up to 10 recipients per workspace
- Theme management — mute or snooze themes as priorities shift
Searchable · archived · annotated
Pricing
Pricing that scales with your team, not your data volume.
Solo
£299/mo
For solo consultants & small comms agencies
- Recipients1
- Sources5
- Daily brief✓
- Weekly summary✓
- Mention alerts—
- Slack delivery—
- Monthly trend PDF—
- Quarterly briefing—
- Curator commentary—
- Custom branding—
- Dashboard (Q3 2026)—
- White-glove onboarding—
Most popular
Team
£799/mo
For sustainability teams at UK B Corps and mid-market firms. Our most popular plan.
- RecipientsUp to 10
- SourcesUnlimited
- Daily brief✓
- Weekly summary✓
- Mention alerts✓
- Slack delivery✓
- Monthly trend PDF✓
- Quarterly briefing✓
- Curator commentary✓
- Custom branding✓
- Dashboard (Q3 2026)—
- White-glove onboarding—
Enterprise
£1,999/mo
Custom sources, white-glove, priority feature requests
- RecipientsUnlimited
- SourcesUnlimited + curation
- Daily brief✓
- Weekly summary✓
- Mention alerts✓
- Slack delivery✓
- Monthly trend PDF✓
- Quarterly briefing✓
- Curator commentary✓
- Custom branding✓
- Dashboard (Q3 2026)Early access
- White-glove onboarding✓
Annual: 2 months free on any tier. Cancel anytime, no minimum term.
Proof & credibility
Real engineering. Real customer. Real team behind it.
Hi, I’m Stephen. I run Granite Marketing, an AI engineering studio. Over the last 6 months we built a vertical news intelligence system for a UK clean energy company (private at their request, but you’d recognise the name). It’s been quietly running their team’s daily sustainability monitoring, replacing about 8 hours of manual scanning per week.
Sightline is that system, productised — built for UK sustainability teams who need the same edge.
Every Sightline customer talks directly to me. I onboard you personally. I respond to feedback within 24 hours. I’m not VC-backed and I’m not pretending to be a 50-person company. What I am is a single engineer with a working system and a few months of customer feedback ahead of every alternative.
- Replaces ~8 hrs/wk of manual scanning
- Running live at a UK clean energy company
- Onboarded personally
- Feedback answered in 24h
FAQ
Common questions
Cortellis and Evaluate are expensive enterprise pharma-intelligence platforms built for market-access and BD teams reading raw filings — not a daily curated read for R&D. A PubMed or Google Scholar alert just dumps keyword matches with no context and no “why this matters to you” framing. Sightline is purpose-built for the intelligence problem — what to read, when, and why it matters to your specific pipeline.
Generic news doesn't know your business. Sightline's classifier is calibrated on YOUR sources, YOUR competitors, YOUR regulators, and YOUR taste (via the eval step). The difference shows up by month 2 — you stop unsubscribing from the digest.
Yes — your data is encrypted in transit and at rest, on EU-hosted infrastructure. You own your data and can export or delete it at any time. We don't use it to train shared models. Full GDPR + ICO compliant.
Workspace stays for 30 days as read-only (in case you change your mind), then permanently deleted. No data hostage, no clawback emails.
Self-serve sign-up isn’t live yet — but you don’t need a sales call to see what Sightline produces. Email Stephen with the subject “sample briefs” and we’ll send you a sample feed plus example weekly, monthly, and quarterly briefs, so you can see the shape of what would land in your inbox. Every early customer still gets a hands-on onboarding when they’re ready — a 20-min walkthrough with Stephen, or a recorded demo once those are up. The goal isn’t to gatekeep, it’s to make sure the eval is tuned to your business before the digests start.
Stephen Anindo, founder of Granite Marketing. Solo founder, UK-based, building production AI/automation systems for clients for several years. Sightline is my first product company.
Next quarter: a live dashboard for browsing historical briefs, automated monthly recalibration of your eval, and native Slack + Teams apps. Later this year: digest engagement analytics, white-label branded emails, and multi-recipient permission tiers (admin / curator / viewer). North Star is to be what Bloomberg Terminal is to finance, but for biotech R&D — the canonical morning read for R&D leaders.
Book a demo — tomorrow starts at 06:00
See Sightline on your business in 20 minutes.
Pick a slot below and Stephen will walk you through how Sightline would set up against your sources, your competitors, and your regulators.
Loading calendar…
Prefer to reach out directly? Email Stephen — usually responds within 24 hours.
Not ready for a call? Request access — we’ll be in touch when your workspace is ready.